Abstract: The present invention relates to the treatment of cancers. Specifically, the invention pertains to a method for the extracorporeal treatment of one or more body fluids in two stages, characterized by removing a body fluid from a living body diseased with a type of cancer, passing the body fluid through a first stage, applying an anti-angiogenesis, anti-tumorigenesis, anti-metastasis, or chemotherapeutic treatment to at least one antigen in the body fluid. More specifically, the treatment comprises creating an antibody-antigen moiety during passage through the first stage, passing the treated body fluid through a second stage, removing the antibody-antigen moiety from the body fluid during passage through the second stage, and returning the purified body fluid to the body. The invention is further characterized by targeting an antigen in the body fluid, with an antibody to allow and facilitate removal thereof in the second stage.

Abstract: A method is described to treat cancer by extracorporeally treating a bodily fluid of a patient. A patient's body fluid is treated extracorporeally using a moiety that targets an antigen in the bodily fluid. The treatment can include applying an anti-angiogenesis, anti-tumorigenesis, anti-metastasis, or chemotherapeutic treatment to at least one antigen in the bodily fluid. The moiety facilitates removal of the antigen. The cleansed body fluid is then returned to the patient.

Abstract: The present invention relates to the treatment of cancers. Specifically, the invention pertains to a method for the extracorporeal treatment of one or more body fluids (e.g., blood or cerebrospinal fluid, CSF) in two stages characterized by removing a body fluid (e.g., blood or CSF) from a living body diseased with a type of cancer, passing the body fluid through a first stage of applying a treatment to at least one antigen in the body fluid. More specifically, the treatment comprises creating an antibody-antigen moiety during passage thereof through said first stage, passing the treated body fluid through a second stage, removing antibody-antigen moiety from the body fluid during passage through the second stage, and returning the purified body fluid to the body.

Abstract: The present invention relates to an article and method of extracorporeal treating a patient's body fluid, for example, CSF (cerebrospinal fluid), lymph, or blood. The treatment includes a plurality of stages comprising removing the body fluid from a patient, applying an extracorporeal treatment to the body fluid, and returning the body fluid to the patient. In the first stage of the treatment, the body fluid is removed from the patient. A convenient method for removing blood is utilizing standard venipuncture technique. A convenient method for removing CSF is using a standard lumbar puncture. In the second stage, a treatment is applied to the body fluid. The treatment can include an antibody directed against targeted antigen(s)/TA(s). The third stage comprises returning the body fluid to the patient, and can also include removing the treatment from the body fluid.

Abstract: The present invention relates to the treatment of infectious diseases, specifically by extracorporeally eradicating the pathogen. This invention comprises methods for the extracorporeal treatment of infectious diseases that will remove infectious pathogens (leukemia cells, bacteria, viruses, or fungi causing a septicemia, metastatic cancer cells, target protein, viruses, parasites, fungi and prions) in humans by targeting such pathogens with a laser or other high-energy source of emissive radiation. More specifically, the method involves removing a bodily fluid from a patient, attaching an antibody to pathogens in the bodily fluid, sensing the antibody-pathogen moiety, using a high-powered, focused laser to destroy the antibody-pathogen moiety, removing the remains of the antibody-pathogen by filtering or other suitable mechanism(s), and returning the bodily fluid to the patient.

Abstract: A method is described to treat chronic pain syndromes by treating extracorporeally a patient's cerebrospinal fluid (CSF). A patient's CSF is treated extracorporeally using a moiety that targets an antigen in the CSF. This moiety facilitates removal of the CSF antigen. The cleansed CSF is then returned to the patient.

Abstract: A method is described to treat atherosclerosis by extracorporeally treating a patient's blood. A patient's blood is treated extracorporeally using a moiety that targets an antigen in the blood. The moiety facilitates removal of the blood antigen. The cleansed blood is then returned to the patient.

Abstract: A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain. Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases, such as MS. The treatment comprises about 1-10 mg naltrexone, at least about 20 ?g vitamin B12, at least about 5 mg vitamin B6, at least about 2 mg coenzyme Q, and preferably at least one ancillary medication selected from the group consisting of diazepam, cyclcobenzaprine, clonazepam, alprazolam, 9-tetrahydrocannibinol, fumarate, caffeine, and combinations thereof. The treatment can be administered orally, and can decrease mental and physical symptoms such as, for example, fatigue, gait problems, visual dysfunction, and pain while improving cognitive skills.

Abstract: A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain. Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases, such as MS. The treatment comprises about 1-10 mg naltrexone, at least about 20 ?g vitamin B12, at least about 5 mg vitamin B6, at least about 2 mg coenzyme Q, and preferably at least one ancillary medication selected from the group consisting of diazepam, cyclcobenzaprine, clonazepam, alprazolam, 9-tetrahydrocannibinol, fumarate, caffeine, and combinations thereof. The treatment can be administered orally, and can decrease mental and physical symptoms such as, for example, fatigue, gait problems, visual dysfunction, and pain while improving cognitive skills.

Abstract: The present invention relates to a treatment of multiple sclerosis, and includes the extracorporeal treatment of one or more body fluids, such as, for example blood, cerebral-spinal fluid, or lymphatic fluid. A treatment is applied to the extracorporeal body fluid where the treatment targets at least one target multiple sclerosis antigen in the body fluid. The treatment can include creating an antibody-antigen moiety and then removing antibody-antigen moiety from the body fluid before returning the body fluid to a patient.

Abstract: A filter and a method to treat blood borne carcinomas by inducing apoptosis in carcinoma cells. The filter includes a stent having an interior wall defining a channel containing a packing material and at least one antineoplastic agent. The method includes placing a patient's blood in apposition of the antineoplastic agent by pumping the blood through the stent. The blood remains in apposition to the antineoplastic agent for a sufficient time period to induce an apoptotic cascade.

Abstract: The invention describes a method to treat an extracorporeally body fluid. The body fluid can include, for example, blood, cerebral spinal fluid and lymph. A first stage of the method applies a treatment to the extracorporeal body fluid. The treatment comprises combining at least one antibody with a CA antigen to produce an antibody-CA antigen moiety. A second stage of the method substantially removes the antibody-CA antigen moiety from the extracorporeal body fluid.

Abstract: A filter and a method treat blood borne carcinomas by inducing apoptosis in carcinoma cells. The filter includes comprises a stent having an interior wall defining a channel containing a packing material and at least one antineoplastic agent. The method includes placing a patient's blood in apposition of the antineoplastic agent by pumping the blood through the stent. The blood remains in apposition to the antineoplastic agent for a sufficient time period to induce an apoptotic cascade.

Abstract: A method is described to treat tauopathies by extracorporeally treating a patient's cerebrospinal fluid (CSF). The method includes introducing an antibody into the CSF that is targeted to an antigen associated with tauopathies. The antibody can include an albumin moiety, and targets the removal of antigens such as tau protein, phosphorylated tau (pTau) protein, Ubiquitin and PKN. The antibody-antigen complex can be removed from the CSF and the CSF can be returned to the patient.

Abstract: An article and method to treat extracorporeally a patient's bodily fluid. The bodily fluid can include blood, cerebral spinal fluid and lymph. A first stage of the method includes applying a treatment. The treatment can comprise dosing with a medication, thermal treatment, or irradiation. The treatment can occur at levels that could otherwise compromise the patient's health. A second stage of the method substantially removes the treatment from the bodily fluid. The bodily fluid can then be returned to the patient. The article includes a treatment chamber that applies the treatment and a removal module for removing the treatment. The method can be a continuous process such as, for example, a dialysis process.

Abstract: An article and method to treat extracorporeally a patient's bodily fluid. The bodily fluid can include blood, cerebral spinal fluid and lymph. A first stage of the method includes applying a treatment. The treatment can comprise dosing with a medication, thermal treatment, or irradiation. The treatment can occur at levels that could otherwise compromise the patient's health. A second stage of the method substantially removes the treatment from the bodily fluid. The bodily fluid can then be returned to the patient. The article includes a treatment chamber that applies the treatment and a removal module for removing the treatment. The method can be a continuous process such as, for example, a dialysis process.

Abstract: A filter and a method treat blood borne carcinomas by inducing apoptosis in carcinoma cells. The filter includes comprises a stent having an interior wall defining a channel containing a packing material and at least one antineoplastic agent. The method includes placing a patient's blood in apposition of the antineoplastic agent by pumping the blood through the stent. The blood remains in apposition to the antineoplastic agent for a sufficient time period to induce an apoptotic cascade.

Abstract: A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain. Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases, such as MS. The treatment comprises about 1-10 mg naltrexone, at least about 20 ?g vitamin B12, at least about 5 mg vitamin B6, at least about 2 mg coenzyme Q, and preferably at least one ancillary medication selected from the group consisting of diazepam, cyclcobenzaprine, clonazepam, alprazolam, 9-tetrahydrocannibinol, fumarate, caffeine, and combinations thereof. The treatment can be administered orally, and can decrease mental and physical symptoms such as, for example, fatigue, gait problems, visual dysfunction, and pain while improving cognitive skills.

Abstract: The present invention provides a system of baiting and growing microorganisms on a gelatinous matrix. A bioreactor is provided wherein the bioreactor provides an environment conducive to the breakdown of organic aqueous material and the production of hydrogen from microorganisms and restrictive to the production of methane from methanogens. The bioreactor includes substrates coated with a gelatinous matrix, wherein the gelatinous matrix coating is replenished by additional coating material pumped into interior channels of the substrates wherein the substrates are permeable by the coating.

Abstract: A method of inducing apoptosis in a cell. The method includes providing an impenetrable and nonmetabolizable material, such as paraffin or agar, and introducing the cell into a contacting relationship with the material. The method also includes providing a substrate and coating the substrate with the impenetrable and nonmetabolizable material.